Company
Headquarters: Madrid, Spain
Employees: 477
CEO: Mr. Jose Maria Fernandez Sousa-Faro
€1.31 Billion
EUR as of Jan. 1, 2026
US$1.54 Billion
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, rest of Europe, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops clinical-stage programs, including PM184 and PM14. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.
| Last Financial Reports Date | June 30, 2025 |
| Revenue TTM | €179.3 M |
| EBITDA | €21.0 M |
| Gross Profit TTM | €169.5 M |
| Profit Margin | 18.97% |
| Operating Margin | -11.10% |
| Quarterly Revenue Growth | -21.90% |
Pharma Mar, SA has the following listings and related stock indices.
Stock: BME: PHM
Stock: FSX: PMRA
Stock: OTC: PHMMF